Document is current
Any future updates will be listed below
-
Authors
Stelander, Line Tegner http://orcid.org/0000-0001-5721-2811
Høye, Anne
Bramness, Jørgen G.
Selbæk, Geir
Lunde, Linn-Heidi
Wynn, Rolf
Grønli, Ole Kristian
-
Funding
Funding for this research was provided by:
Helse Nord RHF (HNF1467-19)
- License Information
-
More Information
Article History
Accepted: 16 April 2021
First Online: 26 May 2021
Declarations
:
: Not applicable.
: All participants provided written consent to the scientific use of their health survey data. The Tromsø Study has a license from the Norwegian Data Inspectorate and has been approved by the Regional Committee for Medical and Health Research Ethics (REC North). The present study is part of a research project approved by the REC North (case reference 2020/96868). Our study was performed in compliance with the Declaration of Helsinki.
: Geir Selbæk has received honoraria for participating in one meeting of the Norwegian advisory board for Biogen, regarding the aducanumab trials. The other authors declare that they have no competing interests.
